Oxford BioMedica Reaffirms FY2026 Guidance Amid Growth

Guidance and Performance Overview

Oxford BioMedica (LSE:OXB) has reaffirmed its full-year 2026 guidance, projecting revenue between £220-240 million at constant exchange rates. The company confirmed that 60% of this target is already secured through existing client contracts, with coverage rising to over 80% when including its risk-adjusted pipeline. An EBITDA margin of approximately 10% is also expected for the period.

This confirmation comes as the company reported strong 2025 results, with net revenue reaching £168.7 million, a 31% increase year-over-year. The growth was driven by a significant rise in manufacturing, development, and procurement services.

Strategic Moves and Future Outlook

The company has lowered its capital expenditure forecast for 2026-2027 to £50 million from £60 million, a move enabled by the capital-efficient acquisition of a new facility in Durham, USA. Oxford BioMedica's order book grew by 36% to £204 million in 2025, reflecting strong commercial momentum.

Looking ahead, the company anticipates continued revenue growth of 25-30% in both 2027 and 2028, with EBITDA margins projected to exceed 20% in 2027. Analyst confidence remains high, with RBC Capital Markets maintaining an Outperform rating on the stock.

Summary

Oxford BioMedica's reaffirmed guidance and strong 2025 performance underscore its solid market position. With a growing order book and strategic investments, the company is poised for sustained growth in the coming years, targeting significant margin expansion.

FAQ

Q: What is Oxford BioMedica's revenue guidance for fiscal year 2026?
A: The company expects revenue between £220 million and £240 million at constant exchange rates.

Q: How did Oxford BioMedica perform in 2025?
A: The company reported a 31% increase in net revenue to £168.7 million and saw its order book grow by 36%.

Source: Investing.com